ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Midazolam

Also written as “midazolam”, “USL261” and “SHP615”.

Its studies are mostly in Epilepsy · HIV Infections · Diabetes Mellitus, Type 2 · Neoplasms · Nervous System Diseases, led by 10 companies.

Drug pageMidazolam: every studyMany companies study it; this page follows only the 18 they lead. All 426 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jul 1, 200818 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZenecaits history only30 open or runningphase 1since Jul 1, 2008Jul 1, 2008none ahead
Merckits history only30 open or runningphase 1since Jun 17, 2015Jun 17, 2015none ahead
Takedaits history only30 open or runningphase 3since Nov 6, 2017Nov 6, 2017none ahead
Hamad Medicalits history only20 open or runningphase 4since Sep 4, 2016Sep 4, 2016none ahead
Johnson & Johnsonits history only20 open or runningphase 1since Oct 2, 2015Oct 2, 2015none ahead
Merck KGaA, Darmstadt, Germanyits history only10 open or runningphase 1since Aug 9, 2018Aug 9, 2018none ahead
Orion Corporation, Orion Pharmaits history only10 open or runningphase 3since May 31, 2007May 31, 2007none ahead
Phathom Pharmaceuticalsits history only10 open or runningphase 1since Sep 4, 2020Sep 4, 2020none ahead
Rafa Laboratoriesits history only10 open or runningphase 1since Dec 15, 2020Dec 15, 2020none ahead
The Emmes10 open or runningphase 3since Apr 27, 2005Apr 27, 2005none ahead

Also a collaborator on its studies: Arvinas Estrogen Receptor, National Resilience, Takeda Development Center Americas, PRA Health Sciences, Medpace, Premier Research Group and Cross Research.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of The Emmes only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 27, 2005First study: phase 3 study in Critical IllnessFirst studyNCT00109395 · 179 enrolled · United States

TargetBeta

“GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive allosteric modulator”ChEMBL 37, by rule

Other programs on the same 16 targets

ProgramCompanyFurthest phaseStudies
ciprofolruleHaisco Pharmaceutical Groupphase 436
AlprazolamruleViatrisphase 435
brexanoloneruleSupernus Pharmaceuticalsphase 414
DiazepamruleAcorda Therapeuticsphase 39

Studies

The one study The Emmes leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00109395Critical Illness · United States3CompletedSep 2007179

How it is read

Names in the registry

  • “Midazolam”, 64 entries
  • “midazolam”, 13 entries
  • “USL261”, 4 entries
  • “SHP615”, 2 entries
  • “Midazolam Solution”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.